Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Inhibitor/Aspirin GI Safety Study Suggested By FDA Advisory Cmte.

Executive Summary

Additional research is needed on the gastrointestinal safety of concomitant COX-2 inhibitor and aspirin use, FDA's Arthritis Advisory Committee recommended during its Feb. 7-8 review of sNDAs for Pharmacia/Pfizer's Celebrex and Merck's Vioxx.

You may also be interested in...



Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor

Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30

Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor

Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30

Celebrex, Vioxx GI Safety Differences May Be Indistinguishable - FDA Cmte.

Gastrointestinal safety outcome differences between Pharmacia/Pfizer's Celebrex and Merck's Vioxx may be a factor of statistical "technicalities," FDA Arthritis Advisory Committee voting consultant David Wofsy, MD, University of California-San Francisco, suggested.

Related Content

UsernamePublicRestriction

Register

PS037326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel